Experts Flag Malnutrition Gap in GLP-1 Use

University of Newcastle researchers say Australia is not tracking the extent of malnutrition and muscle loss linked to GLP-1 weight-loss drugs.

Updated on Nov. 7, 2026 in Weight Loss

Experts Flag Malnutrition Gap in GLP-1 Use

Live Poll

Do you trust doctors to monitor nutrition risks when prescribing weight-loss drugs?

Researchers at the University of Newcastle have identified a critical gap in evidence on malnutrition risks for people using GLP-1 medications such as Ozempic. Millions of Australians are expected to use these drugs, yet the extent of nutrient deficiency and muscle loss is not being tracked.

Why it matters

Common GLP-1 side effects such as fatigue, nausea, diarrhoea and constipation overlap with symptoms of nutrient deficiency, which can make problems harder to recognise. Extreme malnutrition carries risks including brain damage, heart problems and death.

A systematic review led by Laureate Professor Clare Collins assessed the diets of about 50,000 adults taking GLP-1 medications. The review did not establish how widespread malnutrition or muscle loss is among users, as this remains untracked.

The players

University of Newcastle

A public research university in New South Wales whose researchers identified the gap in GLP-1 malnutrition evidence.

Clare Collins

A Laureate Professor and nutrition researcher who led the systematic review of diets among GLP-1 users.

Marley Spoon

An Australian meal-kit company that launched a GLP-1 Support range targeting users of these medications.

The details

Some users have reported nausea, fatigue and weakness linked to nutrient deficiency. One Bendigo user, Emily, was prescribed a GLP-1 through a telehealth appointment, lost a significant amount of weight within a month, and experienced nausea and vomiting before adding protein to her diet and starting strength training.

Timeline

  1. Earlier this year: Guzman y Gomez expanded its mini range for the GLP-1 market.

  2. May: Marley Spoon launched its GLP-1 Support range.

Health Landscape

The rapid uptake of GLP-1 medications such as Ozempic in Australia has outpaced monitoring of their nutritional effects on users. Food companies including Guzman y Gomez and Marley Spoon are already adapting products to this market.

Anyone using a GLP-1 medication should watch for signs of nutrient deficiency, such as persistent fatigue or weakness, and discuss their diet with a healthcare provider. Adding protein and strength training may help protect muscle during weight loss.

The takeaway

Weight loss medications can change how much and what people eat, so monitoring nutrition is as important as monitoring weight. Users who notice unusual fatigue, nausea or weakness should raise these symptoms with a doctor promptly.

Further reading

Explore more on weight loss to see how these medications are being used across the country.

Live Poll

Do you trust doctors to monitor nutrition risks when prescribing weight-loss drugs?